Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Autolus Therapeutics plc

< Previous 1 2 3 Next >
Autolus Therapeutics announces appointment of Robert F. Dolski as Chief Financial Officer
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
Autolus Therapeutics to report second quarter 2023 financial results and host conference call on August 3, 2023
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
Autolus Therapeutics announces a publication in Nature Medicine on obe-cel in Pediatric Acute Lymphoblastic Leukemia
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
Autolus Therapeutics announces publication in Cancer Immunology Research
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
Autolus Therapeutics strengthens its Board with the appointment of Dr. Robert Iannone as a Non-Executive Director
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
Autolus Therapeutics Presents Positive Results from AUTO4 in Relapsed/Refractory TRBC1-Positive Peripheral T-Cell Lymphoma
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
Autolus to hold Annual General Meeting (AGM) of Shareholders on Friday, June 30, 2023
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
Autolus Therapeutics Presents Positive Results from Pivotal Phase 2 FELIX study in adult r/r B-ALL at ASCO
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
Autolus Therapeutics to hold Analyst call to highlight data at ASCO from the Pivotal Phase 2 FELIX study of obe-cel data in adult r/r B-ALL
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
Autolus Therapeutics announces Pivotal Phase 2 FELIX study of obe-cel in adult r/r B-ALL selected for an oral presentation at EHA
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
Autolus Therapeutics Reports First Quarter 2023 Financial Results and Operational Progress
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
Autolus Therapeutics announces Pivotal Phase 2 FELIX study of obe-cel in adult r/r B-ALL selected for an oral presentation at ASCO
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
Autolus Therapeutics Selects Cardinal Health as U.S. Commercial Distribution Partner
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL CAH
Autolus Therapeutics Announces Publication in Molecular Therapy Nucleic Acids
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
Autolus Therapeutics Announces Data from AUTO1/22 Trial in Pediatric Acute Lymphoblastic Leukemia in an Oral Presentation at the EBMT 49th Annual Meeting
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
Autolus Therapeutics to Host Virtual Capital Markets Day
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
Autolus Therapeutics to Report First Quarter 2023 Financial Results and Host Conference Call on May 4, 2023
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
Autolus Therapeutics Announces Publication in Molecular Therapy
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
Autolus Therapeutics announces resignation of Chief Financial Officer
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
Autolus Therapeutics Has No Business Relationship with Silicon Valley Bank
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
Autolus Therapeutics Reports Full Year 2022 Financial Results and Operational Progress
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
Autolus Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on March 7, 2023
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
Autolus Therapeutics announces Board changes
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
Autolus Therapeutics Announces Collaboration with Cabaletta Bio for Use of Autolus’ Safety Switch System in Cell Therapies for Autoimmune Disease
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL CABA
Autolus Announces Partial Exercise of Underwriters' Option to Purchase Additional ADSs
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2022
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
Autolus Announces Pricing of Public Offering
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
Autolus Announces Proposed Public Offering in the United States
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
Autolus Therapeutics to Receive $70 Million in Milestone Payments from Blackstone Life Sciences
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
Autolus Therapeutics announces pivotal Phase 2 FELIX clinical trial has met primary endpoint at interim analysis
From Autolus Therapeutics plc
Via GlobeNewswire
Tickers AUTL
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.